Common Pancreatitis Treatments Show No Benefit Despite Lowering Triglycerides

This comprehensive review challenges current medical practice for treating hypertriglyceridemia-induced acute pancreatitis, a serious condition where extremely high triglyceride levels trigger pancreatic inflammation. The connection between high triglycerides and pancreatitis is well-established, and long-term triglyceride management prevents future episodes.

The authors examined evidence for three widely-used acute treatments: plasmapheresis (blood filtering), intravenous insulin in non-diabetic patients, and heparin therapy. These interventions aim to rapidly reduce triglyceride levels during acute episodes, based on the logical assumption that faster triglyceride reduction would improve outcomes.

Randomized controlled trials consistently showed these treatments effectively lower triglycerides faster than standard supportive care alone. However, none demonstrated meaningful improvements in clinical outcomes like reduced complications, shorter hospital stays, or faster disease resolution.

The findings have significant implications for emergency medicine and gastroenterology practice. These treatments are resource-intensive, expensive, and carry risks including bleeding from heparin, hypoglycemia from insulin, and complications from plasmapheresis procedures.

The authors recommend against using these triglyceride-lowering therapies pending stronger evidence of clinical benefit. This challenges current guidelines and suggests standard supportive care may be equally effective while avoiding unnecessary risks and costs.